Price trend, volume and key moving averages
Trailing total returns as of 11/8/2026, which may include dividends or other distributions. Benchmark is S&P 500 (^GSPC).
Recent results and news deserve attention only when they alter the forward view.
| Quarter | EPS (Act vs Est) | Revenue (Act vs Est) |
|---|---|---|
Q3 2026Latest Aug 12, 2026 | -$0.27+14.3% vs -$0.31 | $3M+269.7% vs $743,308 |
Q2 2026 May 12, 2026 | -$0.34-17.2% vs -$0.29 | $24,422-96.7% vs $743,308 |
Q2 2026 Mar 31, 2026 | -$0.27+10.0% vs -$0.30 | — vs $538 |
Q4 2025 Nov 12, 2025 | -$0.04-29.7% vs -$0.03 | — vs $4,912 |
Connect Biopharma Holdings Limited (CNTB) Discusses Rademikibart and SEABREEZE Trial Results in Acute COPD Transcript
Connect Biopharma Holdings (CNTB) is technically in oversold territory now, so the heavy selling pressure might have exhausted. This along with strong agreement among Wall Street analysts in raising earnings estimates could lead to a trend reversal for the stock.
Connect Biopharma Holdings (CNTB) witnesses a hammer chart pattern, indicating support found by the stock after losing some value lately. This coupled with an upward trend in earnings estimate revisions could mean a trend reversal for the stock in the near term.
Inhibrx Biosciences (NASDAQ: INBX - Get Free Report) and Connect Biopharma (NASDAQ: CNTB - Get Free Report) are both small-cap healthcare companies, but which is the superior stock? We will contrast the two companies based on the strength of their dividends, analyst recommendations, institutional ownership, valuation, earnings, profitability and risk. Volatility and Risk Inhibrx Biosciences has a
Benchmark CNTB against direct peers instead of judging its metrics in isolation.
Key metrics vs top competitors for Connect Biopharma Holdings Limited (CNTB)
| Company | Price | Market Cap | P/E Ratio | Rev Growth (1Y) | Net Margin | ROE | Div Yield |
|---|---|---|---|---|---|---|---|
| $0.73 | $45.88M | -0.73 | -99.75% | -86687.5% | -82.72% | — | |
| $291.31 | $514.68B | 49.87 | 8.57% | 15.68% | — | 2.26% | |
| $904.35 | $93.17B | 19.82 | 0.99% | 28.51% | 15.07% | 0.38% | |
| $25.55 | $3.2B | 116.88 | 91.34% | 5.88% | 14.18% | — | |
| $4.54 | $187.94M | -3.55 | -3.89% | -43.8% | -20.11% | — | |
| $119.65 | $24.25B | 60.28 | 21.22% | 6.71% | 7.11% | — |
Connect Biopharma Holdings Limited (CNTB) vs competitors — business, growth, and fundamentals comparison against the closest industry rivals.
Verify the primary filings, follow material updates, and answer the remaining questions.
Connect Biopharma Holdings Limited (CNTB) SEC filings — annual & quarterly reports (10-K, 10-Q)
Aug 12, 2026·SEC
May 12, 2026·SEC
Apr 23, 2026·SEC
Get notified when CNTB posts new earnings or crosses analyst targets
Free. No account needed. Unsubscribe any time.
Connect Biopharma Holdings Limited (CNTB) stock FAQ — growth, dividends, profitability & financials explained
Connect Biopharma Holdings Limited (CNTB) reported $0.1M in revenue in fiscal year 2025.
Connect Biopharma Holdings Limited (CNTB) revenue fell by 99.8% in fiscal year 2025, compared with the prior fiscal year.
No. Connect Biopharma Holdings Limited (CNTB) reported a net loss of $55.5M in fiscal year 2025.
Connect Biopharma Holdings Limited (CNTB) had a return on equity (ROE) of -82.7% in fiscal year 2025. A negative ROE means the company lost money over the period.
Connect Biopharma Holdings Limited (CNTB) had negative free cash flow of $51.6M in fiscal year 2025.
